Peter from Chile

Registered at the short selling broker Capital, 5 minutes ago.

» Try Capital you too
67.7% of retail investor accounts lose money when trading CFDs with Capital.
Don't show again

GlaxoSmithKline Plc (GSK) shares information


24h Change

-0.51 %


Live rate: Market closed

Stock data per Friday 22 Sep, 2023

-0.19 (-0.51%)
US Market is closed

Live Stock price in graph for GSK Plc – ADR (GSK)

  • Latest Volume

    4,456,468 (2.37 %)

  • Volume prev. day


  • Avg. daily volume


  • Market cap


  • P/E ratio


  • Today high

    37.745 USD

  • Today low

    37.37 USD

  • 52 week high

    38.58 USD

  • 52 week low

    27.37 USD

  • YTD Change

    + 9.21 %

Quick links


Latest news about GSK Plc – ADR

Below you can find the most recent news posts about GSK Plc – ADR, primarily from US and UK based news sources.

Merck Vs. GSK: The Game-Changer Race In Pharma Excellence

Friday, 22 September 2023, 18:14:52
Despite the increasing number of emerging challenges for the pharmaceutical industry, the management teams at GSK and Merck are successfully coping with them. Learn which one is best.
— Seeking Alpha

Price Over Earnings Overview: GSK

Friday, 22 September 2023, 17:00:21
In the current session, the stock is trading at $37.73, after a 0.29% spike. Over the past month, GSK Inc. (NYSE: GSK ) stock increased by 8.51% , and in the past year, by 30.92% . With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued. Comparing GSK P/E Against Its Peers The P/E ratio is used by long-term shareholders to assess the company”s market … Full story available on
— Benzinga

Biotech Stock Roundup: GSK’s Drug Approval, MRNA’s Vaccine News, PTCT & SPRY Down

Friday, 22 September 2023, 04:41:30
It was a busy week for the biotech sector, with a lot of important regulatory and pipeline updates.
— 24/7 Wall street

European Commission authorizes GSK’s HIV prevention drug

Tuesday, 19 September 2023, 22:12:03
close Video Fox News Flash top headlines for September 19 Fox News Flash top headlines are here. Check out what’s clicking on The European Commission has authorized GSK’s HIV-focused unit ViiV Healthcare’s cabotegravir long-acting injectable and tablets, the British drugmaker said on Tuesday. EUROPEAN COMMISSION CHIEF URSULA VON DER LEYEN ASSURES AID TO FLOOD-STRICKEN SLOVENIA DURING VISIT Cabotegravir is recommended in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually-acquired HIV-1 infection in high-risk adults and adolescents weighing at least 77.16 pounds, according to the company. The GlaxoSmithKline logo is seen in this illustration, Aug. 10, 2022. (REUTERS/Dado Ruvic/Illustration/File Photo) Sold under brand name Apretude, it is currently approved for use in the United States, Australia, Zimbabwe, South Africa, Malawi, Botswana and Brazil. CLICK HERE TO GET THE FOX NEWS APP The post European Commission authorizes GSK’s HIV prevention drug appeared first on Samford News .
— Samford Crimson

European Commission authorizes GSK”s HIV prevention drug

Tuesday, 19 September 2023, 21:54:05
The European Commission has granted authorization to GSK”s HIV-focused division, ViiV Healthcare, for its cabotegravir in both long-acting injectable and tablet forms.
— Fox News

Trading broker recommendation

We recommend that you check out as they have a very good selection of stocks available for both going short and long.

Rating: 9.57/10
Minimum deposit: €250 by bank
Description: offer a large number of stocks for trading. Register an account today and check if they have GSK available or trade one of the many other CFD stocks they have.
Risk warning: 67.7% of retail investor accounts lose money when trading CFDs with Capital.